CraniUS Information

CraniUS Therapeutics is developing NeuroPASS, a novel platform designed to enable direct, repeatable access to the brain for targeted therapeutic delivery. The platform is engineered to align with standard neurosurgical workflow while supporting therapies that require precise CNS access. Rather than a single-product strategy, CraniUS is building a scalable platform architecture intended to support multiple future applications across neuro-oncology, neurology, and related CNS disciplines. Our approach emphasizes clinical alignment, disciplined development, and long-term platform value. We are focused on translating surgical insight into a platform that supports more consistent and repeatable access for brain-directed therapies. CraniUS engages selectively with clinicians, partners, and strategic collaborators aligned with advancing next-generation CNS treatment strategies. NOTE – The NeuroPASS platform is an investigational device limited by Federal (or United States) law to investigational use and is not available for commercial distribution.